A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)

Trial Profile

A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Flurpiridaz F 18 (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use; Registrational
  • Sponsors Lantheus Medical Imaging
  • Most Recent Events

    • 11 Apr 2016 Last checked against ClinicalTrials.gov record.
    • 02 Nov 2015 According to a Lantheus Medical Imaging media release, data from a sub-analysis focused on the female sub-population from this study will be presented at the American Heart Association 2015 Scientific Sessions.
    • 04 May 2015 Based on the results of this trial, Lantheus redesigned the protocol for its second phase III study, including different primary endpoints, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top